RP Management LLC:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:RP Management LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10821
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
RP Management LLC (RP Management) is a life sciences financing company that offers biopharmaceutical products. The company’s products include thalomid, myozyme, lexiscan, rituxan, atripla, lyrica, prezista, letairis, januvia, onglyza, neupogen, rotateq, cubicin, savella, and others. It also provides nesina, remicade, humira, galvus, cimzia, mircera, tradjenta, viviant, Xtandi, tecfidera, imbruvica, and priligy. RP Management has interests in approved and late stage development bio-pharmaceutical products. The company offers its products in the therapeutic areas of rheumatoid arthritis (RA), chronic kidney disease, Crohn’s disease, diabetes, HIV/AIDS and others. It operates through research institutions, biotechnology and pharmaceutical companies, and inventors. RP Management is headquartered in New York, the US.

RP Management LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RP Management LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Royalty Pharma Acquires Royalty Streams and Milestones of Products from Zealand Pharma 11
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 13
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 14
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 16
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 18
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 20
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 21
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 22
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 23
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 25
Venture Financing 26
Avillion Secures Funds from Royalty Pharma 26
Private Equity 27
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 27
Equity Offering 28
Immunomedics to Raise USD75 Million in Private Placement of Shares 28
RP Management LLC – Key Competitors 30
RP Management LLC – Key Employees 31
RP Management LLC – Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
RP Management LLC, Pharmaceuticals & Healthcare, Key Facts 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Royalty Pharma Acquires Royalty Streams and Milestones of Products from Zealand Pharma 11
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 13
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 14
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 16
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 18
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 20
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 21
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 22
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 23
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 25
Avillion Secures Funds from Royalty Pharma 26
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 27
Immunomedics to Raise USD75 Million in Private Placement of Shares 28
RP Management LLC, Key Competitors 30
RP Management LLC, Key Employees 31

List of Figures
RP Management LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[RP Management LLC:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Australian Broadcasting Corp:企業の戦略的SWOT分析
    Australian Broadcasting Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • CorMedix Inc (CRMD):企業の財務・戦略的SWOT分析
    Summary CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company offers neutrolin, a non-antibiotic anti-infective developed as a preventative solutio …
  • Cerus Corp (CERS):医療機器:M&Aディール及び事業提携情報
    Summary Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide r …
  • American States Water Company (AWR):企業の財務・戦略的SWOT分析
    Summary American States Water Company (AWR) operates as a utility service provider that offers water, wastewater and electric services. The utility provides operation, construction management and maintenance services for water and wastewater systems located on military bases across the US. It offers …
  • Specialised Therapeutics Australia Pty Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Specialised Therapeutics Australia Pty Ltd (STA) is a biopharmaceutical company that develops and commercializes therapies and technologies for unmet medical needs. The company’s product portfolio includes abraxane, gliolan, oncotype dx, iclusig, oncotype dx prostate and aloxi. Its pipeline …
  • GlySens Inc:医療機器:M&Aディール及び事業提携情報
    Summary GlySens Inc (GlySens) is a medical device company that offers glucose monitoring systems. The company develops GlySens ICGM system, a fully-implanted continuous glucose monitoring system intended to improve the lives of people with diabetes. GlySens offers continuous glucose sensor, which ha …
  • MS&AD Insurance Group Holdings, Inc.:企業の戦略・SWOT・財務情報
    MS&AD Insurance Group Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary MS&AD Insurance Group Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Gevo Inc (GEVO):企業の財務・戦略的SWOT分析
    Summary Gevo Inc (Gevo) is a renewable chemicals and advanced biofuels company that offers renewable chemicals and biofuels. The company’s products include carbon cycle products, low carbon renewable jet fuels, renewable gasoline, isobutanol blendstocks, ingredient products, animal feed and proteins …
  • Heineken UK Ltd:企業の戦略・SWOT・財務情報
    Heineken UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Heineken UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • The GPT Group (GPT):企業の財務・戦略的SWOT分析
    The GPT Group (GPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • OBJ Ltd (OBJ):医療機器:M&Aディール及び事業提携情報
    Summary OBJ Ltd (OBJ) is a developer of magnetic micro-array drug and ingredient delivery technologies. The company offers services such as drug or ingredient profiling in skin, laboratory facilities and capabilities, formulation development, product development, product optimisation, and pre-commer …
  • Enzymatica AB (ENZY):企業の財務・戦略的SWOT分析
    Summary Enzymatica AB (Enzymatica) is a life science company that develops and markets medical products for various virus and bacterial infections. The company offers mouth sprays and veterinary products. Its veterinary products comprise dental health and skin relief enzyme based gels, dental and de …
  • Games Workshop Group PLC (GAW):企業の財務・戦略的SWOT分析
    Summary Games Workshop Group PLC (Games Workshop) is a miniature wargaming products manufacturing company. The company designs, manufactures and distributes fantasy miniatures, metal soldiers and rule books. Its products include warhammer age of sigmar, warhammer 40000, the hobbit, scenery, painting …
  • Municipal Energy Agency of Nebraska:企業の戦略的SWOT分析
    Municipal Energy Agency of Nebraska - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Sahara Petrochemicals Co:企業の戦略的SWOT分析
    Sahara Petrochemicals Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Galp Energia SGPS SA (GALP):企業の財務・戦略的SWOT分析
    Galp Energia SGPS SA (GALP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Matador Resources Co (MTDR):企業の財務・戦略的SWOT分析
    Summary Matador Resources Co (Matador Resources) is an energy company that explores, develops, and produces crude oil and natural gas resources. It offers new oil and natural gas prospects for exploring and developing hydrocarbons in the US basins. In addition, the company carries out exploration, p …
  • EyePoint Pharmaceuticals Inc (PSDV):企業の財務・戦略的SWOT分析
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. EyePoint dura …
  • Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Luxoft Holding Inc:企業の戦略・SWOT・財務情報
    Luxoft Holding Inc - Strategy, SWOT and Corporate Finance Report Summary Luxoft Holding Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆